Loading clinical trials...

Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection | Clinical Trials | Clareo Health

UNKNOWNPHASE1/PHASE2

Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection

Phase1 Study of Recombinant Stem Cells That Repair Lung Injury in H7N9 Infected Patients

NCT02095444•S-Evans Biosciences Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine whether human menstrual blood-derived stem cells are effective in the treatment of infection of H7N9 virus caused acute lung injury.

Detailed Description

1. recruiting volunteers of H7N9 infection: age \> 18; patients signed with the informed consent; APACHE II \> 20 score 2. patients infused with menstrual blood progenitor cells infusion dose: 1\~10×10\*7 cells/kg infusion frequency: 2 times a week, 2 weeks for infusion 3. test items and standard spirits lifted; pulmonary function improved; lung image injury improved

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Clinical diagnosis of H7N9 infection
•must be critical injured for lung tissues

Exclusion Criteria

•cancer diseases
•pregnancy
•mental disorder
•allergic constitution
•severe inflammation

Locations (1)

State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital

Hangzhou, Zhejiang, China

Key Dates

Start Date

March 1, 2014

Primary Completion Date

June 1, 2016

Completion Date

December 1, 2016

Last Updated

March 24, 2014

Enrollment

ESTIMATED participants

Conditions

Acute Lung InjuryAcute Respiratory Distress Syndrome (ARDS)Multiple Organ Failure

Interventions

Menstrual blood stem cells

DRUG

Contacts

Charle Xiang, Doctor

CONTACT

86-571-87236426 cxiang@zju.edu.cn

Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients: A Prospective Evaluation

NCT07414056

Acute Respiratory Distress Syndrome (ARDS)

View study

RECRUITINGPHASE2

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

NCT06701669

Acute Respiratory Distress Syndrome (ARDS)ARDS+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 24, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection

Inclusion Criteria

Exclusion Criteria

Turning Ratios Into Prognosis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Powerful Predictors of ARDS in Pediatric Burn Patients: A Prospective Evaluation

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

Evaluating the Safety and Performance of the MiniLung Petite Kit in Neonatal and Pediatric Patients With Acute Respiratory and Cardiac Failure

Vadadustat for the Treatment of Nonintubated Acute Respiratory Distress Syndrome Due to Pathogen-Associated Lung Injury

A Trial of Staff Time With Proned Patients in the ICU Using the 'BathMat'

RecruitmEnt Assessed by eleCtRical Impedance Tomography